title: Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
abstract: Deutetrabenazine is a derivative of tetrabenazine in which two trideuteromethoxy groups substitute two methoxy groups. The active metabolites of deutetrabenazine have a longer half-life than those of tetrabenazine, together with a greater overall absorption. However, the peak plasma concentrations are lower. Because of these pharmacokinetic differences, deutetrabenazine can be given twice daily, thus improving compliance. The lower peak concentrations may account for a lower incidence of some unwanted adverse effects. Unlike tetrabenazine, deutetrabenazine has no effect on the QT interval. Treatment with deutetrabenazine significantly improved chorea in Huntington's disease, the hyperkinetic features of tardive dyskinesia, and tics in Tourette syndrome. In all three conditions, deutetrabenazine produced an acceptable level of overall adverse effects without causing any severe adverse effects.
authors.affiliation: University of Auckland School of Medical Sciences, Pharmacology & Clinical Pharmacology Auckland, New Zealand. dmpaton38@yahoo.ca.
authors.forename: D M
authors.initials: DM
authors.lastname: Paton
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D017277:Drug Approval; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006816:Huntington Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006948:Hyperkinesis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D015394:Molecular Structure; D009043:Motor Activity / Q000187:drug effects*; D013329:Structure-Activity Relationship; D000071057:Tardive Dyskinesia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013747:Tetrabenazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D005879:Tourette Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D018759:Adrenergic Uptake Inhibitors; C000609690:deutetrabenazine; D013747:Tetrabenazine
keywords: Deutetrabenazine; Huntington's disease; Hyperkinetic disorders; Tardive dyskinesia; Tourette syndrome